LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals’ NEXTERONE® (amiodarone HCL) Premixed Injection, which recently received supplemental new drug application (sNDA) approval from the U.S. Food and Drug Administration, makes use of the patent-protected CyDex Captisol® technology platform. The new product is a premixed intravenous (IV) bag formulation of Prism Pharmaceuticals’ NEXTERONE Injection, which was the first CyDex licensed proprietary product to achieve NDA approval.
